Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a company focused on developing innovative treatments for seizure disorders, announced the addition of a new patent to its intellectual property portfolio. The United States Patent and Trademark Office (USPTO) has granted a patent for ZTALMY® (ganaxolone) oral titration regimens, covering the treatment of various epilepsy disorders, including CDKL5 deficiency disorder, tuberous sclerosis complex (TSC), and Lennox-Gastaut syndrome (LGS). This patent (U.S. Patent No. 12,115,169) is set to expire in September 2042.
“This new patent strengthens the intellectual property protection for ZTALMY and aligns with our plans to develop and commercialize ganaxolone for TSC and other unmet medical needs like LGS,” said Scott Braunstein, M.D., Chairman and CEO of Marinus. “The patent represents decades of research and innovation, backed by strong pharmacology data and clinical dosing results. The USPTO’s recognition of the novel titration regimens highlights their potential to improve tolerability, compliance, and patient outcomes across a range of epilepsy disorders.”
About Marinus Pharmaceuticals
Marinus is a commercial-stage pharmaceutical company dedicated to developing therapies for seizure disorders. ZTALMY® (ganaxolone) oral suspension CV, FDA-approved in 2022, is the company’s flagship product.
